Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Ad-SGE-REIC Gene Therapy for Malignant Pleural Mesothelioma
jRCT2080222946Phase 2
- Sponsor
- Kyorin Pharmaceutical
- Start
- Aug 2015
- Modality
- Adenoviral Vectors → Other Viral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of MTG201 in pleural mesothelioma (3 arms), sponsored by Kyorin Pharmaceutical.
02
Drugs
MTG201
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on jRCT2080222946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222946.